PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Alphamab Oncology (9966.HK)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINKYG0330A1013
SectorHealthcare
IndustryBiotechnology

Highlights

Market CapHK$4.32B
Revenue (TTM)HK$249.74M
Gross Profit (TTM)HK$142.99M
EBITDA (TTM)-HK$285.03M
Year RangeHK$3.81 - HK$17.34
Target PriceHK$10.05

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds to compare with 9966.HK

Alphamab Oncology

Performance

Performance Chart

The chart shows the growth of an initial investment of HK$10,000 in Alphamab Oncology, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-50.00%0.00%50.00%OctoberNovemberDecember2024FebruaryMarch
-66.44%
66.32%
9966.HK (Alphamab Oncology)
Benchmark (^GSPC)

S&P 500

Returns By Period

Alphamab Oncology had a return of -31.78% year-to-date (YTD) and -67.64% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-31.78%10.16%
1 month-13.05%3.47%
6 months-49.94%22.20%
1 year-67.64%30.45%
5 years (annualized)N/A13.16%
10 years (annualized)N/A10.89%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-40.51%27.09%
2023-4.00%-0.35%33.72%-45.13%5.23%

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

This table presents risk-adjusted performance metrics for Alphamab Oncology (9966.HK) and compares them with a selected benchmark (^GSPC). These performance indicators assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
9966.HK
Alphamab Oncology
-0.93
^GSPC
S&P 500
2.79

Sharpe Ratio

The current Alphamab Oncology Sharpe ratio is -0.93. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00OctoberNovemberDecember2024FebruaryMarch
-0.93
2.77
9966.HK (Alphamab Oncology)
Benchmark (^GSPC)

Dividends

Dividend History


Alphamab Oncology doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-80.00%-60.00%-40.00%-20.00%0.00%OctoberNovemberDecember2024FebruaryMarch
-83.68%
0
9966.HK (Alphamab Oncology)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Alphamab Oncology. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Alphamab Oncology was 86.09%, occurring on Feb 5, 2024. The portfolio has not yet recovered.

The current Alphamab Oncology drawdown is 83.68%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-86.09%Jul 15, 2021632Feb 5, 2024
-56.75%May 21, 2020226Apr 20, 202123May 24, 2021249
-30.77%Feb 27, 202016Mar 19, 202037May 15, 202053
-22.29%May 25, 20219Jun 4, 202113Jun 24, 202122
-13.51%Dec 17, 201917Jan 13, 202018Feb 10, 202035

Volatility

Volatility Chart

The current Alphamab Oncology volatility is 14.65%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%OctoberNovemberDecember2024FebruaryMarch
14.65%
2.80%
9966.HK (Alphamab Oncology)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Alphamab Oncology over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items